-
Something wrong with this record ?
Je tříměsíční léčba cyklofosfamidem dostatečná z hlediska snížení rizika relapsů ANCA-pozitivní renální vaskulitidy?
David Jayne et al.
Language Czech Country Czech Republic
Document type Multicenter Study
- MeSH
- Azathioprine adverse effects therapeutic use MeSH
- Cyclophosphamide adverse effects therapeutic use MeSH
- Adult MeSH
- Financing, Organized MeSH
- Glucocorticoids therapeutic use MeSH
- Immunosuppressive Agents adverse effects therapeutic use MeSH
- Remission Induction MeSH
- Clinical Trials as Topic MeSH
- Drug Therapy, Combination MeSH
- Middle Aged MeSH
- Humans MeSH
- Neutropenia chemically induced MeSH
- Prednisolone therapeutic use MeSH
- Antibodies, Antineutrophil Cytoplasmic blood MeSH
- Randomized Controlled Trials as Topic MeSH
- Recurrence MeSH
- Aged MeSH
- Vasculitis drug therapy immunology mortality MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Multicenter Study MeSH
BACKGROUND: The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. METHODS: We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. RESULTS: Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and in 7 patients in the cyclophosphamide group during the remission phase (10 percent, P=0.94 for the comparison between groups during the remission phase). The relapse rate was lower among the patients with microscopic polyangiitis than among those with Wegener's granulomatosis (P=0.03). CONCLUSIONS: In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc10019817
- 003
- CZ-PrNML
- 005
- 20180625073928.0
- 008
- 100908s2003 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Jayne, David $7 xx0225517
- 245 10
- $a Je tříměsíční léčba cyklofosfamidem dostatečná z hlediska snížení rizika relapsů ANCA-pozitivní renální vaskulitidy? / $c David Jayne et al.
- 314 __
- $a Department of Medicine, Addenbrooke's Hospital, Cambridge
- 520 9_
- $a BACKGROUND: The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. METHODS: We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. RESULTS: Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and in 7 patients in the cyclophosphamide group during the remission phase (10 percent, P=0.94 for the comparison between groups during the remission phase). The relapse rate was lower among the patients with microscopic polyangiitis than among those with Wegener's granulomatosis (P=0.03). CONCLUSIONS: In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced.
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protilátky proti cytoplazmě neutrofilů $x krev $7 D019268
- 650 _2
- $a azathioprin $x škodlivé účinky $x terapeutické užití $7 D001379
- 650 _2
- $a cyklofosfamid $x škodlivé účinky $x terapeutické užití $7 D003520
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glukokortikoidy $x terapeutické užití $7 D005938
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x škodlivé účinky $x terapeutické užití $7 D007166
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a neutropenie $x chemicky indukované $7 D009503
- 650 _2
- $a prednisolon $x terapeutické užití $7 D011239
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a vaskulitida $x farmakoterapie $x imunologie $x mortalita $7 D014657
- 655 _2
- $a multicentrická studie $7 D016448
- 773 0_
- $w MED00012709 $t Postgraduální nefrologie $g Roč. 1, č. 3 (2003), s. 5-6 $x 1214-178X
- 910 __
- $a ABA008 $b B 2318 $c 893 $y 7 $z 0
- 990 __
- $a 20100830113932 $b ABA008
- 991 __
- $a 20180625074158 $b ABA008
- 999 __
- $a ok $b bmc $g 768841 $s 632773
- BAS __
- $a 3
- BMC __
- $a 2003 $b 1 $c 3 $d 5-6 $m Postgraduální nefrologie $x MED00012709
- LZP __
- $a 2010-24/mkme